Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy
Marcella Mottolese, Claudio Botti(Catholic University of America), Franco Di Filippo, Cecilia Nisticò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Maria Benevolo(Istituti di Ricovero e Cura a Carattere Scientifico), Paola Papaldo(Cancer Institute (WIA)), Stefania Vasselli(Cancer Institute (WIA)), Simonetta Buglioni, Girolamo Del Monte(Cancer Institute (WIA)), Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 21
Related Papers
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
|The Lancet|2015|202
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin.
|Journal of Clinical Oncology|1988|168
Lonidamine: Efficacy and safety in clinical trials for thetreatment of solid tumors
|Drugs of today|2003|168